person

Alok B.

Country
Norway
Department
Department of Neurology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
3
Sites with multiple studies

Has run more than one trial at 3 of 17 partner sites.

Specializations

Oncology – Advanced Solid Tumors

Investigates therapeutic options for advanced solid tumors spanning lung, gastrointestinal, breast, and urothelial sites.

  • Checkpoint inhibitor‑based regimens
  • KRAS‑G12C targeted therapies
  • Biomarker‑guided treatment pathways

Emphasis is placed on integrating immunotherapy with chemotherapy and novel targeted agents.

Hematologic Malignancies – Myeloma and Leukemia

Focuses on innovative approaches for multiple myeloma and acute leukemias, including refractory disease settings.

  • Proteasome inhibitor combinations
  • CD38‑directed bispecific antibodies
  • FLT3‑targeted kinase inhibitors

Projects aim to improve depth of response and prolong survival in high‑risk patients.

Neurology – Neurodegenerative and Cerebrovascular Disorders

Leverages expertise from the Department of Neurology to address conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and acute ischemic stroke.

  • Neuroprotective agent trials
  • Disease‑modifying therapies for dementia
  • Acute reperfusion strategies for stroke

Research integrates clinical outcomes with biomarker assessments to guide treatment selection.

Cardiovascular & Renal – Stroke, Atrial Fibrillation, Heart Failure, CKD

Explores interventions for cardiovascular and renal disease intersections, including anticoagulation in chronic kidney disease.

  • Novel oral anticoagulants in atrial fibrillation
  • Anti‑inflammatory agents for heart failure with preserved ejection fraction
  • Renoprotective combos for stage 5 CKD

Studies target reduction of thrombo‑embolic events and preservation of renal function.

Autoimmune & Inflammatory – Rheumatology and Dermatology

Addresses chronic immune‑mediated conditions such as rheumatoid arthritis, Sjögren’s syndrome, and hidradenitis suppurativa.

  • Therapeutic drug monitoring for biologics
  • Targeted cytokine inhibition
  • Topical and systemic treatments for skin inflammation

Efforts aim to achieve sustained disease control while minimizing adverse effects.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.